Insmed (NASDAQ:INSM) CEO William Lewis Sells 10,699 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the transaction, the chief executive officer owned 301,185 shares in the company, valued at $43,361,604.45. This trade represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

William Lewis also recently made the following trade(s):

• On Monday, April 6th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $163.22, for a total value of $1,746,290.78.
• On Thursday, March 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $143.52, for a total value of $1,535,520.48.
• On Thursday, March 5th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $146.03, for a total value of $1,562,374.97.
• On Thursday, February 19th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $150.97, for a total value of $1,615,228.03.
• On Monday, February 9th, William Lewis sold 13,396 shares of Insmed stock. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84.
• On Tuesday, February 3rd, William Lewis sold 3,009 shares of Insmed stock. The stock was sold at an average price of $156.34, for a total value of $470,427.06.
• On Tuesday, January 20th, William Lewis sold 10,699 shares of Insmed stock. The stock was sold at an average price of $158.93, for a total value of $1,700,392.07.

Insmed Stock Performance

Insmed stock opened at $144.48 on Friday. The stock’s 50-day moving average is $149.95 and its 200-day moving average is $167.31. The company has a market cap of $31.19 billion, a price-to-earnings ratio of -22.54 and a beta of 1.10. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. Insmed, Inc. has a 12 month low of $63.81 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business’s revenue for the quarter was up 152.6% compared to the same quarter last year. During the same quarter last year, the business earned ($1.32) earnings per share. Equities analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

A number of large investors have recently modified their holdings of the stock. CIBC Private Wealth Group LLC grew its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares in the last quarter. Kingsview Wealth Management LLC grew its stake in Insmed by 2.7% during the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 60 shares in the last quarter. Choreo LLC grew its stake in Insmed by 2.9% during the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after purchasing an additional 65 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 69 shares in the last quarter. Finally, ORG Partners LLC grew its stake in Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 74 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Wells Fargo & Company cut their price objective on Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday, March 23rd. Leerink Partners increased their target price on Insmed from $210.00 to $215.00 and gave the company an “outperform” rating in a research note on Tuesday, March 24th. Barclays increased their target price on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. UBS Group lowered their target price on Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research note on Tuesday, January 6th. Finally, Truist Financial set a $205.00 target price on Insmed in a research note on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $213.23.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.